The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- **Prioritized**: Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- **Phased**: Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- **Published**: Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. Here is how this deal stacks up.

**Deal Summary**

**Parties**: Pfizer-BioNTech and European Commission

**Date**: November 11, 2020

**Terms of Agreement**: Pfizer and BioNTech reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against COVID-19 to European Union (EU) Member States, with an option for the European Commission to request an additional 100 million doses. Deliveries are anticipated to start by the end of 2020. Financial details have not been disclosed.

<table>
<thead>
<tr>
<th>METRIC</th>
<th>SCORE</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prioritized</td>
<td>0</td>
<td>200m doses would cover over 22% of the European Union’s population with a 2-dose regimen, exceeding the 3% initial allocation threshold and the threshold to prioritize the most vulnerable 20% population.</td>
</tr>
<tr>
<td>Phased</td>
<td>1</td>
<td>The deal provides 200 million doses of the vaccine, and an option to request additional 100 million doses, with deliveries starting by the end of 2020.</td>
</tr>
<tr>
<td>Published</td>
<td>0</td>
<td>The EC has not listed details about the terms of deal and pricing online, but an EU official indicated the price per dose is less than $19.50. Pfizer and BioNTech have not disclosed their pricing model.</td>
</tr>
</tbody>
</table>

**Total Score: 1 out of 6**

While the EU has negotiated strong conditions on liability and non-exclusivity in its Pfizer-BioNTech contract, the deal does little to ensure the initial supply of vaccines isn’t monopolized by the EU. Subsequent deals could be improved by purchasing against global population allocation guidelines and specifying timeline for delivery.

Pfizer and BioNTech could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure additional doses aren’t purchased before other countries have secured deals for portions of the initial supply.

Check out the full methodology and scores for other deals, countries, and companies at [ONE.org/VaccineAccessTest](http://ONE.org/VaccineAccessTest)
Check out the full methodology and scores for other deals, countries, and companies at ONE.org/VaccineAccessTest